Medical - Devices
Compare Stocks
5 / 10Stock Comparison
EDAP vs GKOS vs ATRC vs ISRG vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
EDAP vs GKOS vs ATRC vs ISRG vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $156M | $7.85B | $1.41B | $161.07B | $112.69B |
| Revenue (TTM) | $70M | $551M | $552M | $10.58B | $25.12B |
| Net Income (TTM) | $-13M | $-189M | $-5M | $2.98B | $3.25B |
| Gross Margin | 46.8% | 78.1% | 75.5% | 66.3% | 63.5% |
| Operating Margin | -38.2% | -15.6% | -0.4% | 30.5% | 22.4% |
| Forward P/E | — | — | 370.7x | 43.8x | 19.6x |
| Total Debt | $28M | $140M | $88M | $303M | $14.86B |
| Cash & Equiv. | $17M | $91M | $167M | $3.37B | $4.01B |
EDAP vs GKOS vs ATRC vs ISRG vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Edap Tms S.a. (EDAP) | 100 | 154.1 | +54.1% |
| Glaukos Corporation (GKOS) | 100 | 344.2 | +244.2% |
| AtriCure, Inc. (ATRC) | 100 | 58.1 | -41.9% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| Stryker Corporation (SYK) | 100 | 150.3 | +50.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EDAP vs GKOS vs ATRC vs ISRG vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EDAP ranks third and is worth considering specifically for momentum.
- +80.9% vs SYK's -22.5%
GKOS is the clearest fit if your priority is growth exposure.
- Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
- 32.3% revenue growth vs EDAP's 10.3%
Among these 5 stocks, ATRC doesn't own a clear edge in any measured category.
ISRG is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 5.5% 10Y total return vs GKOS's 457.1%
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- Beta 1.02, current ratio 4.87x
- 28.2% margin vs GKOS's -34.3%
SYK carries the broadest edge in this set and is the clearest fit for income & stability and valuation efficiency.
- Dividend streak 34 yrs, beta 0.55, yield 1.1%
- PEG 1.32 vs ISRG's 2.01
- Lower P/E (19.6x vs 43.8x), PEG 1.32 vs 2.01
- Beta 0.55 vs GKOS's 1.20
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.3% revenue growth vs EDAP's 10.3% | |
| Value | Lower P/E (19.6x vs 43.8x), PEG 1.32 vs 2.01 | |
| Quality / Margins | 28.2% margin vs GKOS's -34.3% | |
| Stability / Safety | Beta 0.55 vs GKOS's 1.20 | |
| Dividends | 1.1% yield; 34-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +80.9% vs SYK's -22.5% | |
| Efficiency (ROA) | 14.8% ROA vs GKOS's -20.1%, ROIC 15.0% vs -9.2% |
EDAP vs GKOS vs ATRC vs ISRG vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EDAP vs GKOS vs ATRC vs ISRG vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
SYK leads 1 • GKOS leads 1 • EDAP leads 0 • ATRC leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 360.9x EDAP's $70M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $70M | $551M | $552M | $10.6B | $25.1B |
| EBITDAEarnings before interest/tax | -$24M | -$40M | $13M | $3.8B | $6.3B |
| Net IncomeAfter-tax profit | -$13M | -$189M | -$5M | $3.0B | $3.2B |
| Free Cash FlowCash after capex | -$17M | -$18M | $54M | $2.8B | $4.3B |
| Gross MarginGross profit ÷ Revenue | +46.8% | +78.1% | +75.5% | +66.3% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -38.2% | -15.6% | -0.4% | +30.5% | +22.4% |
| Net MarginNet income ÷ Revenue | -18.9% | -34.3% | -0.8% | +28.2% | +12.9% |
| FCF MarginFCF ÷ Revenue | -25.1% | -3.4% | +9.7% | +26.8% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +31.4% | +41.2% | +14.3% | +23.0% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.3% | -6.3% | +101.6% | +18.8% | +56.0% |
Valuation Metrics
SYK leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 35.0x trailing earnings, SYK trades at a 39% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs ISRG's 2.65x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $156M | $7.9B | $1.4B | $161.1B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | $166M | $7.9B | $1.3B | $158.0B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -5.33x | -40.90x | -115.83x | 57.62x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 370.67x | 43.84x | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.65x | 2.36x |
| EV / EBITDAEnterprise value multiple | — | — | 77.75x | 43.62x | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 2.20x | 15.47x | 2.63x | 16.00x | 4.49x |
| Price / BookPrice ÷ Book value/share | 8.02x | 11.69x | 2.70x | 9.17x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 29.15x | 64.67x | 26.31x |
Profitability & Efficiency
ISRG leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-65 for EDAP. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to EDAP's 1.43x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs GKOS's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -65.4% | -26.5% | -1.0% | +16.9% | +15.0% |
| ROA (TTM)Return on assets | -18.8% | -20.1% | -0.7% | +14.8% | +6.9% |
| ROICReturn on invested capital | -69.2% | -9.2% | -0.6% | +15.0% | +11.4% |
| ROCEReturn on capital employed | -56.0% | -10.3% | -0.6% | +16.5% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.43x | 0.21x | 0.18x | 0.02x | 0.66x |
| Net DebtTotal debt minus cash | $10M | $49M | -$79M | -$3.1B | $10.8B |
| Cash & Equiv.Liquid assets | $17M | $91M | $167M | $3.4B | $4.0B |
| Total DebtShort + long-term debt | $28M | $140M | $88M | $303M | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | -18.69x | 0.47x | — | 6.72x |
Total Returns (Dividends Reinvested)
GKOS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $3,579 for ATRC. Over the past 12 months, EDAP leads with a +80.9% total return vs SYK's -22.5%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs EDAP's -28.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +22.4% | +21.2% | -29.2% | -19.3% | -15.2% |
| 1-Year ReturnPast 12 months | +80.9% | +52.0% | -8.3% | -15.4% | -22.5% |
| 3-Year ReturnCumulative with dividends | -63.3% | +128.7% | -41.8% | +49.6% | +5.5% |
| 5-Year ReturnCumulative with dividends | -37.8% | +61.5% | -64.2% | +58.7% | +21.5% |
| 10-Year ReturnCumulative with dividends | +18.9% | +457.1% | +95.1% | +554.2% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -28.4% | +31.7% | -16.5% | +14.4% | +1.8% |
Risk & Volatility
Evenly matched — GKOS and SYK each lead in 1 of 2 comparable metrics.
Risk & Volatility
SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than GKOS's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GKOS currently trades 91.4% from its 52-week high vs ATRC's 64.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.77x | 1.20x | 1.03x | 1.02x | 0.55x |
| 52-Week HighHighest price in past year | $5.05 | $146.75 | $43.18 | $603.88 | $404.87 |
| 52-Week LowLowest price in past year | $1.21 | $73.16 | $26.62 | $427.84 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +82.4% | +91.4% | +64.4% | +75.1% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 63.0 | 45.0 | 42.4 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 38K | 678K | 669K | 1.8M | 2.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: EDAP as "Buy", GKOS as "Buy", ATRC as "Buy", ISRG as "Buy", SYK as "Buy". Consensus price targets imply 82.3% upside for ATRC (target: $51) vs 9.3% for GKOS (target: $147). SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.00 | $146.67 | $50.67 | $622.60 | $403.69 |
| # AnalystsCovering analysts | 8 | 24 | 19 | 55 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.8% | +1.4% | 0.0% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SYK leads in 1 (Valuation Metrics). 1 tied.
EDAP vs GKOS vs ATRC vs ISRG vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EDAP or GKOS or ATRC or ISRG or SYK a better buy right now?
For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.
3% revenue growth year-over-year, versus 10. 3% for Edap Tms S. a. (EDAP). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Edap Tms S. a. (EDAP) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EDAP or GKOS or ATRC or ISRG or SYK?
On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.
0x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Stryker Corporation is actually cheaper at 19. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — EDAP or GKOS or ATRC or ISRG or SYK?
Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.
5%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus EDAP's +18. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EDAP or GKOS or ATRC or ISRG or SYK?
By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.
55β versus Glaukos Corporation's 1. 20β — meaning GKOS is approximately 119% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 143% for Edap Tms S. a. — giving it more financial flexibility in a downturn.
05Which is growing faster — EDAP or GKOS or ATRC or ISRG or SYK?
By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.
3% versus 10. 3% for Edap Tms S. a. (EDAP). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -52. 9% for Edap Tms S. a.. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EDAP or GKOS or ATRC or ISRG or SYK?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -41. 5% for Edap Tms S. a. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -35. 6% for EDAP. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EDAP or GKOS or ATRC or ISRG or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 6x forward P/E versus 370. 7x for AtriCure, Inc. — 351. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.
08Which pays a better dividend — EDAP or GKOS or ATRC or ISRG or SYK?
In this comparison, SYK (1.
1% yield) pays a dividend. EDAP, GKOS, ATRC, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is EDAP or GKOS or ATRC or ISRG or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, ATRC: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EDAP and GKOS and ATRC and ISRG and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EDAP is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while EDAP, GKOS, ATRC, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.